TY - JOUR
T1 - Mild cognitive impairment (part 2)
T2 - Biological markers for diagnosis and prediction of dementia in Alzheimer's disease
AU - Forlenza, Orestes V.
AU - Diniz, Breno S.
AU - Teixeira, Antonio L.
AU - Stella, Florindo
AU - Gattaz, Wagner
PY - 2013
Y1 - 2013
N2 - To present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings.
AB - To present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings.
KW - Alzheimer's disease
KW - Amyloid-β protein
KW - Biomarkers
KW - Mild cognitive impairment
KW - Neuroimaging
KW - Tau protein
UR - http://www.scopus.com/inward/record.url?scp=84885119225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885119225&partnerID=8YFLogxK
U2 - 10.1590/1516-4446-2012-3505
DO - 10.1590/1516-4446-2012-3505
M3 - Article
C2 - 24142092
AN - SCOPUS:84885119225
SN - 1516-4446
VL - 35
SP - 284
EP - 294
JO - Revista Brasileira de Psiquiatria
JF - Revista Brasileira de Psiquiatria
IS - 3
ER -